FDA hits pause on Protagonist's blood cancer med after mouse study turns up skin tumors

Protagonist Therapeutics’ treatment for a rare, slow-growing blood cancer is under an FDA clinical hold after the company reported safety concerns in a nonclinical mouse study.

The mice in the study developed benign and malignant skin tumors, the company announced in a statement Friday. The FDA verbally told the company about the hold, Protagonist said.